In the Media

September 21, 2021

Is the industry ready for synthesized cannabinoids?

InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, and talks about whether the industry is ready for synthesized cannabinoids.

Read the article and watch the full video at The Dales Report.

Source: The Dales Report

Share this post

Latest Articles

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,

December 11, 2024

Study on Anti-Inflammation by Modulation of Endocannabinoid System

A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.

December 10, 2024

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

September 4, 2024